Lucid-MS moves toward clinical trial in US that will enroll MS patients
Quantum Biopharma is preparing to seek FDA clearance for a U.S. clinical trial of Lucid-MS, an oral therapy designed to target myelin loss and promote repair in multiple sclerosis.
Quantum Biopharma soon will seek FDA clearance to launch a U.S. clinical trial evaluating Lucid-MS, an oral therapy designed to slow myelin loss and support repair in multiple sclerosis.
Key facts
- Quantum Biopharma plans to submit an investigational new drug (IND) application to the FDA in the coming weeks.
- The planned study is a Phase 2 clinical trial in the United States.
- Lucid-MS is a first-in-class oral therapy designed to target myelin loss and promote myelin repair.
- Salvatore Napoli, MD, has been named principal investigator for the trial.
Quantum Biopharma soon will be seeking FDA clearance to launch a clinical trial testing its oral therapy Lucid-MS in people with multiple sclerosis. Lucid-MS is a first-in-class therapy designed to target myelin loss and promote its repair. The developer has named an internationally known neurologist from Massachusetts as the trial’s principal investigator.
Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the progressive disease.
The company said it expects to submit an investigational new drug (IND) application, which includes the full design of the planned Phase 2 trial, to the U.S. Food and Drug Administration (FDA) in the coming weeks.
If cleared by the regulatory agency, the trial will test the therapy’s safety, tolerability, and potential effectiveness in people living with the disease. As part of preparations for the study, Quantum also announced the appointment of Salvatore Napoli, MD, an internationally known neurologist, as the trial’s principal investigator, according to a company press release.
Lucid-MS targets myelin loss and repair in progressive multiple sclerosis
Lucid-MS is being positioned as a first-in-class oral therapy focused on one of the central biological drivers of multiple sclerosis: myelin loss. By aiming to slow demyelination and promote myelin repair, Quantum Biopharma is advancing a treatment strategy intended to address disease progression and the neurological problems associated with MS.
“The appointment of Dr. Napoli represents a key milestone as we advance Lucid-MS toward clinical evaluation,” said Zeeshan Saeed, CEO of Quantum. “As we prepare for a planned Phase 2 study, our focus is on targeting biological processes associated with disease progression in MS.”
Saeed added that the company believes the program underscores the potential of its approach to addressing areas of high unmet need in neurodegenerative disease. That language reflects Quantum’s broader ambition to position Lucid-MS not simply as another experimental MS therapy, but as a treatment candidate that could intervene in the underlying biological processes linked to progression.
Salvatore Napoli to lead planned U.S. Phase 2 study
Napoli, who Quantum calls a key opinion leader in MS, is the president and medical director of the Neurology Center of New England and the MS Center of New England, where he oversees clinical and research programs focused on advancing innovative treatments for MS and other neurodegenerative diseases.
He completed fellowship training in MS and neuroimmunology at Brigham and Women’s Hospital in Massachusetts and has held academic appointments at Harvard Medical School. By appointing Napoli as principal investigator, Quantum Biopharma is linking the Lucid-MS program with a recognized neurologist whose background spans clinical care, research leadership and academic medicine.
“Disease progression and demyelination remain areas of significant unmet medical need in MS, and Dr. Napoli’s expertise will be invaluable as we prepare for clinical evaluation of Lucid-MS,” said Andrzej Chruscinski, MD, PhD, vice president of clinical and scientific affairs at Quantum. “We are pleased to collaborate with Dr. Napoli as we advance our clinical development program.”
Quantum Biopharma prepares next regulatory step with FDA
The planned IND submission represents the next major regulatory milestone for Lucid-MS in the United States. If the FDA clears the application, Quantum Biopharma will be able to begin its Phase 2 clinical trial and generate human data on safety, tolerability and potential efficacy in people living with multiple sclerosis.
More broadly, the move signals that Lucid-MS is progressing from preclinical and development-stage positioning toward formal clinical evaluation. For Quantum, the upcoming FDA submission and the selection of a principal investigator suggest that operational planning for the study is already well advanced, with the company now preparing to test whether Lucid-MS can translate its therapeutic rationale into measurable clinical benefit for MS patients.
